{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:16:17Z","timestamp":1780550177346,"version":"3.54.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA022453, R37 CA220482, T32-CA009531"],"award-info":[{"award-number":["P30 CA022453, R37 CA220482, T32-CA009531"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The immune cytokine interleukin-12 (IL-12) is involved in cancer initiation and progression, autoimmunity, as well as graft versus host disease. The ability to monitor IL-12 <jats:italic>via<\/jats:italic> imaging may provide insight into various immune processes, including levels of antitumor immunity, inflammation, and infection due to its functions in immune signaling. Here, we report the development and preclinical evaluation of an antibody-based IL-12-specific positron emission tomography (PET) tracer. To mimic localized infection and stimulate IL-12 production, BALB\/c mice were administered lipopolysaccharide (LPS) intramuscularly. [<jats:sup>89<\/jats:sup>Zr]Zr-DFO-\u03b1IL12 tracer was given one hour post LPS administration and PET images were taken after 5, 24, 48, and 72 hours. We observed significantly higher uptake in LPS-treated mice as compared to controls. Biodistribution of the tracer was evaluated in a separate cohort of mice, where tracer uptake was elevated in muscle, spleen, lymph nodes, and intestines after LPS administration. To evaluate the utility of [<jats:sup>89<\/jats:sup>Zr]Zr-DFO-\u03b1IL12 as an indicator of antigen presenting cell activation after cancer immunotherapy, we compared PET imaging with and without intratumoral delivery of oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor (Adv\/GM-CSF), which we have shown promotes anti-tumor immunity. BALB\/c mice were inoculated orthotopically with the mouse mammary carcinoma line TUBO. Once TUBO tumors reached a volume of ~50 mm<jats:sup>3<\/jats:sup>, mice were treated with either three intratumoral injections of 10<jats:sup>8<\/jats:sup> PFU Adv\/GM-CSF or vehicle control, given every other day. Upon the last dose, [<jats:sup>89<\/jats:sup>Zr]Zr-DFO-\u03b1IL12 was injected intravenously and 72 hours later all mice were imaged <jats:italic>via<\/jats:italic> PET. Tumor-specific uptake of [<jats:sup>89<\/jats:sup>Zr]Zr-DFO-\u03b1IL12 was higher in Adv\/GM-CSF treated mice versus controls. Tissues were harvested after imaging, and elevated levels of macrophages and CD8<jats:sup>+<\/jats:sup> T<jats:sub>c<\/jats:sub> cells were detected in Adv\/GM-CSF treated tumors by immunohistochemistry. We validated that IL-12 expression was induced after Adv\/GM-CSF by qRT-PCR. Importantly, expression of genes activated by IL-12 (IFN\u03b3, TNF\u03b1, and IL-18) were unaffected after IL-12 imaging relative to mice receiving an IgG control tracer, suggesting the tracer antibody does not significantly disrupt signaling. Our results indicate that targeting soluble cytokines such as IL-12 by PET imaging with antibody tracers may serve as a noninvasive method to evaluate the function of the immune milieu <jats:italic>in situ<\/jats:italic>.<\/jats:p>","DOI":"10.3389\/fimmu.2022.870110","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T10:32:05Z","timestamp":1652265125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses"],"prefix":"10.3389","volume":"13","author":[{"given":"Nerissa T.","family":"Viola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Glassbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhansi R.","family":"Kalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin B.","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison N.","family":"Wicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32835dbaaf","article-title":"Ipilimumab in Cancer Patients: The Issue of Early Metabolic Response","volume":"24","author":"Chargari","year":"2013","journal-title":"Anticancer Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.10.003","article-title":"Early Positron Emission Tomography\/Computed Tomography as a Predictor of Response After CTL019 Chimeric Antigen Receptor -T-Cell Therapy in B-Cell non-Hodgkin Lymphomas","volume":"20","author":"Shah","year":"2018","journal-title":"Cytotherapy"},{"key":"B3","article-title":"An Update on the Role of (18)F-FDG-PET\/CT in Major Infectious and Inflammatory Diseases","volume":"9","author":"Kung","year":"2019","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2021.06.008","article-title":"Limitations and Pitfalls of FDG-PET\/CT in Infection and Inflammation","volume":"51","author":"Pijl","year":"2021","journal-title":"Semin Nucl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.092809","article-title":"PET With the 89Zr-Labeled Transforming Growth Factor-\u03b2 Antibody Fresolimumab in Tumor Models","volume":"52","author":"Oude Munnink","year":"2011","journal-title":"J Nucl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3346","article-title":"Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response","volume":"77","author":"Larimer","year":"2017","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0253","article-title":"Ifn\u03b3 PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy","volume":"78","author":"Gibson","year":"2018","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219287","article-title":"Immuno-PET of Innate Immune Markers CD11b and IL-1\u03b2 Detects Inflammation in Murine Colitis","volume":"60","author":"Dmochowska","year":"2019","journal-title":"J Nucl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00894","article-title":"Longitudinal [18f]FB-IL-2 PET Imaging to Assess the Immunopathogenicity of O'nyong-Nyong Virus Infection","volume":"11","author":"Chan","year":"2020","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13020167","article-title":"IL-12 Family Cytokines in Cancer and Immunotherapy","volume":"13","author":"Mirlekar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The Immunobiology of the Interleukin-12 Family: Room for Discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00988","article-title":"The IL-12 Cytokine and Receptor Family in Graft-Vs.-Host Disease","volume":"10","author":"Bastian","year":"2019","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M400320200","article-title":"Activation and Repression of Interleukin-12 P40 Transcription by Erythroid Kruppel-Like Factor in Macrophages","volume":"279","author":"Luo","year":"2004","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.17179\/excli2020-3104","article-title":"Immunology of IL-12: An Update on Functional Activities and Implications for Disease","volume":"19","author":"Ullrich","year":"2020","journal-title":"Excli J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), a Cytokine With Multiple Biologic Effects on Human Lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0157175","DOI":"10.1371\/journal.pone.0157175","article-title":"Exposure of Human CD4 T Cells to IL-12 Results in Enhanced TCR-Induced Cytokine Production, Altered TCR Signaling, and Increased Oxidative Metabolism","volume":"11","author":"Vacaflores","year":"2016","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the Regulation of Innate Resistance and Adaptive Immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molimm.2016.11.008","article-title":"Pretreatment of Activated Human CD8 T Cells With IL-12 Leads to Enhanced TCR-Induced Signaling and Cytokine Production","volume":"81","author":"Vacaflores","year":"2017","journal-title":"Mol Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nri2225","article-title":"How Microorganisms Tip the Balance Between Interleukin-12 Family Members","volume":"8","author":"Goriely","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1357","article-title":"IL-12 Rapidly Alters the Functional Profile of Tumor-Associated and Tumor-Infiltrating Macrophages In Vitro and In Vivo","volume":"178","author":"Watkins","year":"2007","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03429.x","article-title":"The Role of Interleukin-12 on Modulating Myeloid-Derived Suppressor Cells, Increasing Overall Survival and Reducing Metastasis","volume":"133","author":"Steding","year":"2011","journal-title":"Immunology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0735","article-title":"Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts","volume":"70","author":"Kerkar","year":"2010","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.119867","article-title":"Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology","volume":"54","author":"Viola-Villegas","year":"2013","journal-title":"J Nucl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1021\/mp500164r","article-title":"Noninvasive Imaging of PSMA in Prostate Tumors With (89)Zr-Labeled Huj591 Engineered Antibody Fragments: The Faster Alternatives","volume":"11","author":"Viola-Villegas","year":"2014","journal-title":"Mol Pharm"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e984523","DOI":"10.4161\/2162402X.2014.984523","article-title":"Immunotherapeutic Intervention With Oncolytic Adenovirus in Mouse Mammary Tumors","volume":"4","author":"Gibson","year":"2015","journal-title":"Oncoimmunology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An Open-Source Platform for Biological-Image Analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btx180","article-title":"Trainable Weka Segmentation: A Machine Learning Tool for Microscopy Pixel Classification","volume":"33","author":"Arganda-Carreras","year":"2017","journal-title":"Bioinformatics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1086\/649557","article-title":"Resilience to Bacterial Infection: Difference Between Species Could be Due to Proteins in Serum","volume":"201","author":"Warren","year":"2010","journal-title":"J Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.12.7504","article-title":"IL-12 Suppression During Experimental Endotoxin Tolerance: Dendritic Cell Loss and Macrophage Hyporesponsiveness","volume":"166","author":"Wysocka","year":"2001","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4008.bloodjournal84124008","article-title":"Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes","volume":"84","author":"Trinchieri","year":"1994","journal-title":"Blood"},{"key":"B31","article-title":"Interleukin-12. Biologic Activity, Therapeutic Utility, and Role in Disease","volume":"72","author":"Hendrzak","year":"1995","journal-title":"Lab Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.13.040195.001343","article-title":"Interleukin-12: A Proinflammatory Cytokine With Immunoregulatory Functions That Bridge Innate Resistance and Antigen-Specific Adaptive Immunity","volume":"13","author":"Trinchieri","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.1.147","article-title":"The Interleukin 12 P40 Gene Promoter is Primed by Interferon Gamma in Monocytic Cells","volume":"183","author":"Ma","year":"1996","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.00991.x","article-title":"Interferon-Gamma (IFN-Gamma) and Prostaglandin E2 (PGE2) Regulate Differently IL-12 Production in Human Intestinal Lamina Propria Mononuclear Cells (LPMC)","volume":"117","author":"Monteleone","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1006\/cyto.1999.0515","article-title":"Interferon Gamma Priming is Not Critical for IL-12 Production of Murine Spleen Cells","volume":"12","author":"Hino","year":"2000","journal-title":"Cytokine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"11302","DOI":"10.1073\/pnas.93.21.11302","article-title":"Adenovirus-Mediated Interleukin-12 Gene Therapy for Metastatic Colon Carcinoma","volume":"93","author":"Caruso","year":"1996","journal-title":"Proc Natl Acad Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.4049\/jimmunol.1402603","article-title":"Intratumoral Delivery of IL-21 Overcomes Anti-Her2\/Neu Resistance Through Shifting Tumor-Associated Macrophages From M2 to M1 Phenotype","volume":"194","author":"Xu","year":"2015","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.8.5245","article-title":"Granulocyte-Macrophage Colony-Stimulating Factor (CSF) and Macrophage CSF-Dependent Macrophage Phenotypes Display Differences in Cytokine Profiles and Transcription Factor Activities: Implications for CSF Blockade in Inflammation","volume":"178","author":"Fleetwood","year":"2007","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.4049\/jimmunol.166.9.5515","article-title":"IL-12 Enhances CD8 T Cell Homeostatic Expansion","volume":"166","author":"Kieper","year":"2001","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.7.2541","article-title":"Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12-Associated Toxicity and Interferon-Gamma Production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1089\/107999001750169934","article-title":"Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon-Alpha 2a for Patients With Advanced Renal Cell Carcinoma","volume":"21","author":"Motzer","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0394-0","article-title":"Priming of Naive CD8+ T Cells in the Presence of IL-12 Selectively Enhances the Survival of CD8+CD62Lhi Cells and Results in Superior Anti-Tumor Activity in a Tolerogenic Murine Model","volume":"57","author":"D\u00edaz-Montero","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B43","doi-asserted-by":"publisher","first-page":"104042","DOI":"10.1016\/j.cellimm.2020.104042","article-title":"Dual-Target IL-12-Containing Nanoparticles Enhance T Cell Functions for Cancer Immunotherapy","volume":"349","author":"Li","year":"2020","journal-title":"Cell Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3050","article-title":"Local Delivery of Interleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice","volume":"18","author":"Chinnasamy","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010858","article-title":"A 52-Week Trial Comparing Briakinumab With Methotrexate in Patients With Psoriasis","volume":"365","author":"Reich","year":"2011","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S102141","article-title":"Ustekinumab in Treatment of Crohn's Disease: Design, Development, and Potential Place in Therapy","volume":"10","author":"Deepak","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and Safety of Ustekinumab, A Human Interleukin-12\/23 Monoclonal Antibody, in Patients With Psoriasis: 76-Week Results From a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and Safety of Ustekinumab, A Human Interleukin-12\/23 Monoclonal Antibody, in Patients With Psoriasis: 52-Week Results From a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0149","article-title":"A Review of Ustekinumab in the Treatment of Psoriatic Arthritis","volume":"10","author":"Roberts","year":"2018","journal-title":"Immunotherapy"},{"key":"B51","doi-asserted-by":"publisher","first-page":"4953120","DOI":"10.1155\/2016\/4953120","article-title":"Treatment With a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model","volume":"2016","author":"Castro-Mej\u00eda","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.870110\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T10:32:20Z","timestamp":1652265140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.870110\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2022.870110"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.870110","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"article-number":"870110"}}